Recent performance snapshot

Elevance Health (ELV) has attracted attention after a 4.4% gain over the past month and a 33.5% move in the past 3 months, with the stock last closing at US$389.03.

That short term momentum, with a 4.4% 1 month share price return and a stronger 33.5% 3 month share price return from US$389.03, contrasts with a more modest 4.9% 1 year total shareholder return and a weaker 3 year record. This hints that sentiment has improved recently, even though longer term holders have seen mixed results.

If Elevance Health’s moves have you looking wider across healthcare, this could be a good moment to scan for other insurers and care platforms linked to AI trends using 39 healthcare AI stocks

With Elevance Health trading at US$389.03, a value score of 5, and an intrinsic value estimate indicating the stock is at a 63.1% discount, is there a potential opportunity here, or is future growth already reflected in the price?

Most Popular Narrative: 0.3% Overvalued

Elevance Health’s most followed narrative pegs fair value at about $387.85, almost in line with the last close at $389.03, which leaves very little valuation gap.

Strategic investments in digital consumer engagement and Carelon's diversified health services (e.g., pharmacy, care management, behavioral health) are accelerating revenue growth and providing higher-margin, recurring income streams. These dynamics are expected to support both topline and earnings diversity as industry healthcare spending and complexity continue to rise.

Want to see what is really baked into that fair value number? The narrative leans on a specific earnings path, margin reset, and a tighter future valuation multiple. The exact mix of those three inputs may surprise you.

Result: Fair Value of $387.85 (OVERVALUED)

However, there is still the risk that elevated medical costs in ACA and Medicaid, or slower than expected Medicaid rate recovery, could challenge that fair value story.

Another View: What Do Earnings Multiples Say?

The narrative and analyst framework suggest Elevance Health is slightly overvalued around $389.03, yet on plain earnings, the stock looks more forgiving. It trades on a P/E of 16.1x versus 22.9x for the US Healthcare industry and a 36.1x peer average, while the fair ratio is 30.7x.

If the market ever moved closer to that fair ratio, the gap from 16.1x to 30.7x could close meaningfully, but there is also the risk that Elevance is priced lower for a reason. Which story do you think is closer to reality for the next few years?

Next Steps

With this mixed sentiment in mind, now is a good time to look at the numbers yourself and decide where you stand. To see what investors are currently optimistic about, check out the 4 key rewards

Looking for more investment ideas?

If Elevance Health caught your attention, do not stop here. Use this momentum to widen your watchlist and pressure test your thesis across other opportunities.

• Target quality at a discount by scanning 46 high quality undervalued stocks and compare how other companies with strong fundamentals are currently priced.
• Strengthen your focus on resilience by reviewing 63 resilient stocks with low risk scores for stocks with lower risk scores that might suit a steadier approach.
• Spot potential future standouts early by checking the screener containing 22 high quality undiscovered gems before the wider market pays attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.